Electric Fields Supercharge Immune Assault on Brain Cancer

Research suggests electric fields, via Tumor Treating Fields (TTFields), may boost immune responses against glioblastoma. It seems likely th...

- ADVERTISEMENT -

• Research suggests electric fields, via Tumor Treating Fields (TTFields), may boost immune responses against glioblastoma.
• It seems likely that combining TTFields with immunotherapy and chemotherapy extends survival, especially for inoperable tumors.
• The evidence leans toward TTFields enhancing T cell activity, potentially revolutionizing brain cancer treatment.
• Controversy exists around cost, accessibility, and long-term side effects, with ongoing Phase 3 trials to confirm benefits.

What is Glioblastoma?
Glioblastoma is the deadliest brain cancer, growing fast and hard to treat, with an average survival of just eight months. It affects about 12,000 people yearly in the US, mostly older adults, and often resists standard treatments like surgery, radiation, and chemotherapy.

The New Approach: Electric Fields and Immune Boost
A 2025 study from Keck Medicine of USC found that using Tumor Treating Fields (TTFields)—low-intensity electric waves delivered via a scalp device—along with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) can significantly help. TTFields disrupt cancer cell division and seem to attract more immune cells, like T cells, to fight the tumor, especially when combined with drugs that enhance immune activity.

Survival Boost and Hope for Inoperable Cases
Patients in the study lived about 10 months longer on average, with a 70% survival increase. For those with large, inoperable tumors, the benefit was even bigger, living 13 months longer, showing stronger immune responses compared to surgically treated patients.

What’s Next?
A larger Phase 3 trial is underway, aiming to enroll over 740 patients by April 2029, to see if this approach can become standard care. It’s exciting, but challenges like cost and side effects, like skin irritation, need addressing.

Introduction: The Glioblastoma Challenge and Recent Breakthrough

As of June 17, 2025, glioblastoma remains one of the most formidable challenges in oncology, with a median survival of eight months post-diagnosis, as reported by the National Brain Tumor Society . This aggressive brain cancer, classified as a grade IV tumor by the WHO, is characterized by rapid growth, diffuse infiltration, and resistance to conventional treatments. A recent study from Keck Medicine of USC, published in Med (DOI: 10.1016/j.medj.2025.100708), has unveiled a promising therapeutic avenue: combining Tumor Treating Fields (TTFields) therapy with immunotherapy (pembrolizumab) and chemotherapy (temozolomide). This Phase 2 trial, known as 2-THE-TOP (NCT03405792), demonstrated a 70% increase in overall survival, particularly for patients with inoperable tumors, by enhancing the immune system’s ability to attack cancer cells.

This detailed analysis explores the science behind TTFields, the methodology and results of the study, and the broader implications for brain cancer treatment, aiming to provide a comprehensive understanding for researchers, clinicians, and patients.

Understanding Glioblastoma: Epidemiology and Prognosis

Glioblastoma, also known as glioblastoma multiforme (GBM), arises from glial cells and accounts for 15% of primary brain tumors and 46% of malignant brain tumors. In the US, approximately 12,000 people are diagnosed annually, with a peak incidence at age 64, and a slight male predominance . The prognosis is grim, with a five-year survival rate of less than 5%, due to the tumor’s aggressive growth, infiltration into surrounding brain tissue, and resistance to therapy.

Current standard treatments include surgery, radiation, and chemotherapy (temozolomide), but each has significant limitations:

• Surgery often cannot remove all tumor tissue due to its diffuse nature, with high recurrence rates.
• Radiation causes cognitive decline and fatigue, and resistance develops over time.
• Chemotherapy efficacy is limited by resistance, and immunotherapy has been ineffective due to the brain’s immunosuppressive environment.

This backdrop underscores the urgent need for innovative treatments, setting the stage for the TTFields breakthrough.

Tumor Treating Fields (TTFields): Technology and Mechanism

TTFields therapy, developed by Novocure, uses low-intensity, alternating electric fields delivered via mesh electrodes on the scalp, worn approximately 18 hours per day. Approved by the FDA in 2011 for recurrent glioblastoma and in 2015 for newly diagnosed cases, TTFields disrupt cancer cell division during mitosis, causing cell death while sparing healthy cells .

The mechanism involves interfering with mitotic spindle assembly and other cellular structures, exploiting the rapid division rate of cancer cells. Recent research suggests TTFields also alter the tumor microenvironment, increasing immunogenicity and inducing immunogenic cell death, which releases signals to activate the immune system .

The 2-THE-TOP Phase 2 Trial: Methodology and Results

The 2-THE-TOP trial (NCT03405792) enrolled 31 patients with newly diagnosed glioblastoma, with 26 receiving the triple therapy: TTFields, pembrolizumab (anti-PD-1 immunotherapy), and temozolomide. Treatment involved:

• TTFields for ~18 hours/day, delivering fields focused on the tumor.
• Temozolomide every four weeks for up to 24 months.
• Pembrolizumab every three weeks starting with the second chemotherapy dose, up to 24 months.

Key results included:

• A 70% increase in overall survival compared to historical data with TTFields and chemotherapy alone, with patients living ~10 months longer.
• For the high-risk subgroup (7 patients with inoperable tumors), survival extended by ~13 months, showing stronger immune activation.

The study found TTFields attract more tumor-fighting T cells, enhancing pembrolizumab’s effectiveness, suggesting a synergistic effect.

Mechanisms: Enhancing Immune Response

TTFields increase tumor immunogenicity, inducing immunogenic cell death and recruiting T cells. Pembrolizumab blocks PD-1, enhancing T cell activity, while temozolomide damages DNA, sensitizing tumors. This synergy creates a potent immune assault, particularly effective for inoperable tumors .

Implications for Inoperable Tumors

Patients with inoperable tumors, historically with poor outcomes, benefited most, living 13 months longer and showing stronger immune responses, suggesting TTFields could redefine treatment paradigms .

Future Directions and Challenges

A Phase 3 trial (NCT06556563) aims to enroll >740 patients by April 2029, potentially leading to standard care adoption. Challenges include side effects (skin irritation, fatigue), patient compliance (18 hours/day device use), and cost/accessibility, with therapy costing tens of thousands monthly .

Conclusion

This breakthrough offers hope for glioblastoma patients, extending survival via TTFields, immunotherapy, and chemotherapy, especially for inoperable cases. Ongoing research and addressing challenges will be crucial for widespread adoption.

Key Citations

• Shocking brain cancer breakthrough: Electric fields supercharge immune assault | ScienceDaily
• Electric Fields May Help the Immune System Fight Brain Cancer | Technology Networks
• Can Electric Fields Supercharge the Immune Response Against the Most | Bioengineer
• Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer? | Newswise
• USC study unlocks new potential treatment for glioblastoma | Keck Medicine News
• Brain cancer breakthrough as experts discover new electric therapy for deadliest disease | Daily Star
• Breakthrough in treatment approach showing promise in the fight against glioblastoma | Mayo Clinic Blog
• Electric Fields May Help the Immune System Fight Brain Cancer | Technology Networks News

- ADVERTISEMENT -